Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hepatology
•
Metabolic Dysfunction-Associated Liver Diseases
What clinical, imaging, or serologic markers would be an indication to you to stop GLP-1 therapy for management of MASLD?
Related Questions
What testing do you utilize to decide a patient's candidacy for Resmetirom therapy?
What is your approach on the pursuit of bariatric surgery in a patient with advanced fibrosis?
If you do not have easy access to shear wave elastography (aka Fibroscan), what do you recommend for non-invasive tests to determine if a MASLD patient has clinically significant portal hypertension and risk-stratify them?
How do you incorporate other pharmacologic bariatric / appetite suppressants in the context of their clinical care plan for MASLD?
How does a patient who is PNPLA-3 positive (heterozygote or homozygote) impact how you formulate their therapeutic plan?
How do you approach a patient with discordant Fibroscan and serologic testing for fibrosis?
How do you approach a patient's candidacy for simultaneous liver transplant and bariatric surgery if MASLD is the etiology of their end-stage liver disease?
What are your biggest takeaways from the MASH-TAG 2025 conference?
How does managing a patient with concomitant alcohol related liver disease impact your choice of therapies?
How does presence of clinically significant portal hypertension change patient prognosis in MASLD?
